Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

× No keyword cloud information.

4 in total

Review 1. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

Authors: S M Grundy; R Pasternak; P Greenland; S Smith; V Fuster
Journal: Circulation Date: 1999-09-28 Impact factor: 29.690

2. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors: J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal: CMAJ Date: 2000-05-16 Impact factor: 8.262

3. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors: G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal: JAMA Date: 2001-04-04 Impact factor: 56.272

4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors:
Journal: Lancet Date: 2002-07-06 Impact factor: 79.321

4 in total

87 in total

1. Dyslipidemia guidelines.

Authors: Hugh R Hindle
Journal: CMAJ Date: 2004-07-20 Impact factor: 8.262

2. Dyslipidemia guidelines.

Authors: Celio Levyman
Journal: CMAJ Date: 2004-07-20 Impact factor: 8.262

3. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors: Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal: Can J Cardiol Date: 2006-09 Impact factor: 5.223

4. The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.

Authors: Glen J Pearson; Gordon A Francis; Jacques S Romney; Dawna M Gilchrist; Andrea Opgenorth; Gabor T Gyenes
Journal: Can J Cardiol Date: 2006-09 Impact factor: 5.223

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

Review 1. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

2. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

3. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

1. Dyslipidemia guidelines.

2. Dyslipidemia guidelines.

3. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

4. The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.

5. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women.

6. Questioning the benefits of statins.

7. The analysis by Manuel and colleagues creates controversy with headlines, not data.

8. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.

9. Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events.

10. Statin use in Canadians: trends, determinants and persistence.